Latest News

Bio-Path Holdings Advances RNAi Therapeutics with Promising Treatments for Cancer and Metabolic Diseases
Bio-Path Holdings, Inc. is making strides in RNA interference therapeutics with its DNAbilize® platform, offering new hope for treating cancer, obesity, and type 2 diabetes through targeted therapy.